Viatris Inc. plans to discuss the buyout of Pacira Biosciences Inc. during its third-quarter earnings call Nov. 5, but the ...

Worldwide drug approvals totaled 38 in August 2026, compared to 39 in August 2025 and 52 in August 2024. Through the first eight months of 2026, global approvals totaled 337, down 6.4% from 360 during ...

A team of researchers from The Ottawa Hospital Research Institute shed some light on a potential association between the ...

The FDA has awarded orphan drug designation to Vtv Therapeutics Inc.’s HPPD (HPP-8668), an investigational, oral, first-in-class Nrf2/Bach1 modulator, for sickle cell disease.

Huadong Medicine presented data for DD-1013, a novel long-acting GLP-1/GIP/amylin receptor triple agonist that was tested in vitro and in vivo for obesity management in diet-induced obese rats.

Dignify Therapeutics LLC has obtained IND clearance from the FDA for DTI-117 for use in neurogenic bowel dysfunction. An ...

That didn’t take long. Just days after the U.S. CMS finalized a rule to test the new GLOBE Model, an alternative rebate formula for certain Medicare Part B drugs, the Pharmaceutical Research and ...

Carving a significant dent into the shares of Argenx SE, the company’s termination of its phase III Sjögren's disease program ...

AI is making headway in the venture capital investment world, taking on first pass due diligence and shaping investor ...

U.S. pricing policy, China’s rise and the growing importance of AI and health data – are creating an opening for Japan to use its scientific strengths to develop and commercialize novel drugs. Strong ...

Medical Microinstruments Inc. (MMI) raised $125 million in a series D financing round to speed up the commercialization of its Symani surgical system. The financing comes as the company enters its ...

Syntara Ltd. reported additional phase II data supporting development of SNT-4728 as a potential disease-modifying therapy for Parkinson's disease, with patients at high risk of developing the ...